Skip to Main Content
Contribute Try STAT+ Today

EQRx — the buzzy biotech company with a lofty mission of making far less expensive look-alike versions of blockbuster drugs — is finally starting to sign deals with insurance companies, a key step toward launching drugs that could shake up the market for medicines. But the deals are light on details, raising questions about just how meaningful that shake-up might eventually be.

The company’s approach to developing drugs relies on “fast followers” — that is, drugs that are extremely similar to approved drugs that can be brought to market more quickly and cheaply than a product that’s breaking new ground. EQRx’s first two drugs for non-small cell lung cancer — aumolertinib and sugemalimab — are approved and pending approval in China, respectively.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment